Search for content, post, videos

InDex, Almirall S.A End Agreement

InDex Pharmaceuticals terminated a license agreement with Almirall S.A. involving the drug candidate Kappaproct® for the treatment of ulcerative colitis. The agreement had given Almirall licensed exclusive rights to Kappaproct® for the European market. Now InDex regains all worldwide development and commercialization rights for Kappaproct®, which is in late-stage clinical development.

“With global rights to Kappaproct® back in our hands, we have all options available regarding the structure of future licensing transactions, which provides strategic leeway in our business development efforts,” said Peter Zerhouni, CEO of InDex Pharmaceuticals. “We have a strong package to offer partners with an interest in inflammation and gastrointestinal diseases such as IBD.”

Kappaproct® is InDex Pharmaceutical’s lead drug candidate and is in late-stage clinical development for moderate to severe ulcerative colitis.